Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

INFANT BACTERIAL THERAPEUTICS AB (PUBL)

(IBT B)
  Report
SummaryQuotesChartsNewsCalendarCompanyFinancials 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Infant Bacterial Therapeutics : CFO leaves the company

05/20/2021 | 10:30am EDT

Infant Bacterial Therapeutics ABs CFO Daniel Mackey has decided to leave the company to pursue new challenges. He will remain in his current role during his notice period. Michael Owens will be acting CFO when Daniel leaves the company and until his replacement is in place. The recruitment process has already been initiated.

“I would like to take this opportunity to thank Daniel and wish him every success in the future”, says Staffan Strömberg, Chief Executive Officer of IBT.

About Infant Bacterial Therapeutics AB
Infant Bacterial Therapeutics AB (publ) is a pharmaceutical company with a product in Phase III with a vision to develop drugs influencing the infant microbiome, and thereby prevent or treat rare diseases affecting infants.

IBT is currently developing the drug candidate IBP-9414, for the prevention of necrotizing enterocolitis (“NEC”) and improvement of feeding tolerance in premature infants. IBP-9414 contains the active substance Lactobacillus reuteri, which is a human bacterial strain naturally present in breast milk. The product portfolio also includes another project, IBP-1016, for the treatment of gastroschisis, a severe and rare disease affecting infants. By developing these drugs, IBT has the potential to fulfill unmet needs for diseases where there are currently no prevention or treatment therapies available.

Infant Bacterial Therapeutics AB (“IBT”) is a public company domiciled in Stockholm. The company’s class B-shares shares are listed on Nasdaq Stockholm, Mid-cap (IBT B).

For additional information please contact
Staffan Strömberg, CEO
Daniel Mackey, CFO
Infant Bacterial Therapeutics AB
Bryggargatan 10
111 21 Stockholm
Phone: +46 70 670 1226
info@ibtherapeutics.com
www.ibtherapeutics.com

Publication

The information was submitted for publication, through the agency of the contact persons set out above, at 16:30 CET on May 20, 2021

Attachment

  • PR 20210520 CFO ENG

© OMX, source GlobeNewswire - EU Press Releases

Stocks mentioned in the article
ChangeLast1st jan.
BIOGAIA AB (PUBL) 0.39% 515 Delayed Quote.-4.10%
INFANT BACTERIAL THERAPEUTICS AB (PUBL) -0.73% 94.7 Delayed Quote.-15.45%
All news about INFANT BACTERIAL THERAPEUTICS AB (PUBL)
07/13INFANT BACTERIAL THERAPEUTICS AB : appoints Marie-Louise Alamaa as new CFO
AQ
07/13Infant Bacterial Therapeutics AB Announces CFO Changes, Effective from August..
CI
05/20INFANT BACTERIAL THERAPEUTICS : CFO leaves the company
AQ
05/20Infant Bacterial Therapeutics AB Announces CFO Changes
CI
05/06INFANT BACTERIAL THERAPEUTICS : Annual General Meeting of Infant Bacterial Thera..
AQ
05/05INFANT BACTERIAL THERAPEUTICS : Annual General Meeting of Infant Bacterial Thera..
AQ
05/05INFANT BACTERIAL THERAPEUTICS AB : (publ) Interim Management Statement, January ..
AQ
05/04INFANT BACTERIAL THERAPEUTICS : Video presentation Annual General Meeting 2021
PU
05/04INFANT BACTERIAL THERAPEUTICS : Annual General Meeting of Infant Bacterial Thera..
AQ
05/04INFANT BACTERIAL THERAPEUTICS AB : (publ) Interim Management Statement, January ..
AQ
More news
Financials
Sales 2020 - - -
Net income 2020 -72,0 M -8,37 M -8,37 M
Net cash 2020 423 M 49,2 M 49,2 M
P/E ratio 2020 -17,5x
Yield 2020 -
Capitalization 1 063 M 124 M 124 M
EV / Sales 2019 -
EV / Sales 2020 -
Nbr of Employees 9
Free-Float 89,5%
Chart INFANT BACTERIAL THERAPEUTICS AB (PUBL)
Duration : Period :
Infant Bacterial Therapeutics AB (publ) Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends INFANT BACTERIAL THERAPEUTICS AB (PUBL)
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Managers and Directors
Staffan Strömberg Chief Executive Officer
Daniel Mackey Chief Financial Officer
Peter Michael Rothschild Chairman
Eamonn Connolly Chief Scientific Officer
Jonas Rastad Chief Medical Officer